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Abstract
Background and Hypothesis: Even within accepted normal ranges, higher serum phosphorus, dietary phosphorus density,
parathyroid hormone (PTH) and alkaline phosphatase (ALP) are independent predictors of cardiovascular mortality. Lower
serum 25-hydroxy vitamin D (25(OH)D) also predicts adverse cardiovascular outcomes. We hypothesized that vascular
dysfunction accompanying subtle disturbances of these bone metabolism parameters would result in associations with
increased low grade albuminuria.
Study Population and Measures: We examined participants in the National Health and Nutrition Examination Surveys
1999–2010 (N = 19,383) with estimated glomerular filtration rate (eGFR) $60 ml/min/1.73 m2 and without severe
albuminuria (urine albumin:creatinine ratio (ACR) ,300 mg/g). Albuminuria was quantified as ACR and fractional albumin
excretion (FEalb).
Results: Increasing quintiles of dietary phosphorus density, serum phosphorus and ALP were not associated with higher
ACR or FEalb. The lowest versus highest quintile of 25(OH)D was associated with greater albuminuria, but not after
adjustment for other covariates including cardiovascular risk factors. An association between the highest versus lowest
quintile of bone-specific ALP and greater ACR persisted after covariate adjustment, but was not accompanied by an
independent association with FEalb. Increasing quintiles of PTH demonstrated associations with both higher ACR and FEalb
that were not abolished by adjusting for covariates including age, gender, race, body mass index, diabetes, blood pressure,
history of cardiovascular disease, smoking, eGFR, 25(OH)D, season of measurement, lipids, hemoglobin and C-reactive
protein. Adjusted increases in ACR and FEalb associated with the highest versus lowest quintile of PTH were 19% (95%
confidence interval 7–28% p,0.001) and 17% (8–31% p= 0.001) respectively.
Conclusion: In this population, of the bone mineral parameters associated with cardiovascular outcomes, only PTH is
independently associated with ACR and FEalb.
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Introduction
Even within accepted normal ranges, higher levels of serum
phosphorus, dietary phosphorus density (phosphorus intake
divided by energy intake), parathyroid hormone (PTH) and
alkaline phosphatase (ALP), independently predict increased risk
of cardiovascular events and mortality[1–10]_ENREF_4_EN-
REF_7. Lower levels of vitamin D (measured as 25-hydroxy
vitamin D, 25(OH)D) also predict substantially increased cardio-
vascular event risk and mortality[11,12]. These observations raise
the possibility that mild disturbances of the bone mineral
metabolic axis contribute to cardiovascular disease and could be
novel targets for disease prevention[3,11]. The mechanisms for
such associations remain unclear. Advanced kidney dysfunction
accompanied by major disturbances in bone mineral metabolism
may promote cardiovascular disease via vascular calcification [13],
but this cannot necessarily be extrapolated to more subtle
differences in bone metabolic parameters_ENREF_3. Among
postulated alternative mechanisms there is some evidence linking
these parameters to adverse effects on vascular endothelium[3,14–
16]_ENREF_14. Endothelium expresses receptors for both PTH
and activated vitamin D, and may be sensitive to direct toxic
effects of elevated phosphate[14]. Since endothelial dysfunction
precedes and accompanies cardiovascular events such as myocar-
dial infarction[17], chronic endothelial exposure to minor, yet
deleterious alterations of such molecules might plausibly explain
their relationship with cardiovascular risk.
Higher urinary albumin excretion rates, even at levels well
below the definition of moderately increased (previously ‘micro’)
albuminuria (30 mg/24 h or a urine albumin:creatinine ratio of
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30 mg/g), predict cardiovascular disease events and mortality[18–
20]. The basis for this finding is uncertain, but has been attributed
to endothelial inflammation/dysfunction leading to increased
glomerular permeability[21–23]. Consequently, if bone mineral
axis dysregulation causes cardiovascular disease through adverse
effects on the endothelium, this would be predicted to increase
low-grade albuminuria. We therefore hypothesized that higher
dietary phosphorus density, serum phosphorus, PTH and ALP
and lower serum 25(OH)D are associated with increased low grade
albuminuria. We tested this hypothesis in subjects with normal
kidney function from a representative US population sample; the
US National Health and Nutrition Examination Surveys
(NHANES).
Methods
Study Population
The US NHANES uses a stratified multistage sampling
procedure to create a study sample representative of the US
non-institutionalized population[24]. Certain demographic sub-
groups (non-Hispanic blacks, Mexican-Americans, and the over
60 s) are oversampled to increase the reliability of analyses in these
groups. For this analysis, data from the continuous NHANES
cycles 1999–2010 were combined. Non-pregnant participants
aged 20 y or older that attended a mobile examination center
(MEC) and were not missing data for weight, height, waist
circumference, blood pressure, serum phosphorus, calcium,
creatinine, CRP, HDL/total cholesterol, ALP, HbA1c, hemoglo-
bin, urine albumin:creatinine ratio (ACR), estimated dietary
phosphorus intake, diabetes status, smoking status, cardiovascular
disease history, poverty:income ratio and time of day of
venepuncture were included in the analysis. In order to determine
whether bone metabolic parameters are associated with increased
albuminuria in the general population, without confounding by
renal pathology, analyses were confined to subjects with preserved
excretory kidney function (estimated glomerular filtration rate
(eGFR) $60 ml/min/1.73 m2 according to the Chronic Kidney
Disease Epidemiology Collaboration eGFR equation[25]) and
normal to moderately increased albuminuria (ACR,300 mg/g).
In additional analyses, the relationships between bone metabolic
parameters and the likelihood of moderately increased albumin-
uria (ACR 30–300 mg/g) were examined.
Parathyroid hormone, 25(OH)D and bone-specific ALP mea-
surements were not performed across all NHANES cycles;
analyses involving these variables were confined to participants
from NHANES 2003–2006 (PTH and 25(OH)D) and 1999–2004
(bone-specific ALP) meeting the other criteria above.
Diabetes was defined as responding ‘Yes’ to the question ‘Have
you ever been told by a doctor or other health professional that
you have diabetes or sugar diabetes?’ or current use of insulin or
oral hypoglycemic agents. Current smoking status was classified
according to the question ‘have you used tobacco or nicotine in the
last 5 days?’ and a history of cardiovascular disease was defined by
yes to any of ‘have you ever been told you had coronary heart
disease/angina/heart attack?’ Race and ethnicity were self-
reported and for the purposes of this work were categorised as
non-Hispanic White, non-Hispanic Black, Hispanic or other.
Participant Measurements
Standing height, weight and waist circumference were mea-
sured on MEC attendance. Blood pressure was taken in a sitting
position after 5 minutes resting, using the average of the 2nd and
3rd of 3 readings. If only one measurement was obtained
successfully, this was used; if only two readings were obtained,
the second was used. A clean-catch random spot urine sample was
collected for albumin and creatinine measurements.
Biochemical Analyses
Analytic procedures for all biochemical parameters are
described in detail on the NHANES website[24]. Blood and urine
samples were aliquoted and stored at 270uC and 220uC
respectively prior to analysis in central laboratories. Serum
phosphorus and intact PTH concentrations were measured by
autoanalyzers using a kinetic ammonium molybdate reaction and
a chemiluminescent sandwich antibody approach respectively.
Serum 25(OH)D concentrations were assayed by radioimmuno-
assay (Diasorin inc., MN), recalibrated across cycles for assay drift.
Total ALP concentration was determined by autoanalyzer
quantification of enzymatic p-Nitrophenylphosphate hydrolysis
and BAP was measured as the activity of antibody-captured
enzyme on colorimetric/fluorescent substrates, with recalibration
of results obtained by different methods. Serum creatinine was
measured using the Jaffe rate method with recalibration across
cycles according to NHANES recommendations[26,27]. Urine
creatinine and albumin were measured by Jaffe rate method and
solid-phase fluorescent immunoassay respectively.
Dietary Intakes Estimates
Dietary intakes of phosphorus and other nutrients over the
preceding 24 h were estimated on the basis of a computer-assisted
recall survey conducted on attendance at the MEC. Nutrient
intakes were calculated from estimated portion sizes and food
types using the Food and Nutrient Database for Dietary
Studies[28]. Only participants with complete dietary data were
included in the analyses. Since dietary phosphorus density (intake
in mg per calorie) shows a stronger association with cardiovascular
mortality than absolute phosphorus intake[4], this was chosen as
the primary assessment of dietary phosphorus exposure.
Statistical Methods
Statistical analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC) and STATA version 11 (StataCorp LP)
incorporating participant sample weights to account for the
complex study design. Log-transformation was applied to non-
normally distributed variables prior to parametric procedures as
appropriate.
Relationships between quintiles of each bone metabolic
parameter and log-transformed ACR were examined by linear
regression. Age, gender and race were included a priori in all
analyses of ACR since these are determinants of creatininuria[29].
In view of previously reported associations between bone mineral
parameters and features of the metabolic syndrome[30–32],
adjustment for body mass index (BMI), weight, waist circumfer-
ence, blood pressure, diabetes status, glycated hemoglobin and
serum lipids was also performed (model 2). Further models
additionally adjusted for other predictors of albuminuria including
smoking status, history of cardiovascular disease, poverty:income
ratio, eGFR, C-reactive protein, calcium and hemoglobin.
Analyses relating to serum phosphorus and PTH included time
of day of venepuncture in the final model since these parameters
follow a diurnal pattern[33,34]. Fasting status is also a determinant
of serum phosphorus[35], so associations between serum phos-
phorus and albuminuria were re-examined in the subpopulation of
NHANES participants assessed in the morning after overnight (at
least 9 hours) fast. Analyses of 25(OH)D associations included
season of measurement and analyses of total ALP included hepatic
transaminases. Since loop and thiazide diuretics may affect
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PTH[36], usages of these medications were incorporated into
models of the association between PTH and albuminuria.
Dietary phosphorus intake analyses were adjusted additionally
for estimated intake of protein; protein and phosphorus intakes are
correlated, but there is some evidence that protein ingestion may
affect albuminuria through glomerular hemodynamic changes
independently of phosphorus[37]. The dietary phosphorus analysis
was also adjusted for estimated intakes of sodium and saturated fat,
which have both been associated with albuminuria in other
studies[38,39].
Increasing serum phosphorus is itself associated with lower
creatinine excretion rate[40], whilst greater PTH and lower
25(OH)D are associated with sarcopenia[41]. Relationships with
spot urine concentrations of both albumin and creatinine were
therefore reported separately, as well as their ratio. To confirm
that conclusions did not simply reflect confounding by creatini-
nuria, analyses were repeated using fractional excretion of albumin
(FEalb) relative to creatinine (i.e. albumin clearance divided by
creatinine clearance, calculated from paired serum and urine
concentrations of both albumin and creatinine). This approach
may be affected by greater proportional tubular creatinine
secretion in the setting of kidney impairment, but is a physiological
measure of renal albumin leak that abolishes confounding effects
of muscle mass[42].
Binary logistic regression was used to determine whether bone
metabolic parameters predicted a greater likelihood of participants
having moderately increased albuminuria (ACR.30 mg/g).
Ethics Statement
The Research Ethics Review Board of the National Center for
Health Statistics approved the NHANES data collection proce-
dures. Written consent was obtained from participants and all data
anonymized.
Results
Participant Characteristics
Of the 27,003 non-pregnant participants .20 y of age in
NHANES 1999–2010 with complete dietary intake and biochem-
istry data, 3,657 (13.5%) had eGFR,60 ml/min/1.73 m2 and
310 (1.3%) with preserved eGFR had severely increased albumin-
uria (ACR.300 mg/g). Further confining the analysis to partic-
ipants with complete data for BMI, waist circumference, blood
pressure, smoking status, diabetes status, history of cardiovascular
disease, poverty:income ratio and time of day of venepuncture
gave a total of n= 19,381 included in the analyses of serum
phosphorus, total ALP and estimated dietary phosphorus intake.
Similar proportions were excluded from the NHANES cycles
combined for PTH, 25(OH)D and BAP analyses, leaving
N=6,005 (NHANES 2003–2006) and N=7,384 (NHANES
1999–2004). Characteristics of the US population represented by
these participants are shown in Table 1 and by quintiles of each
metabolic bone parameter in Tables S1–S6 in File S1.
Urine ACR, creatinine concentration, albumin concentration
and FEalb were all positively skewed and were natural log-
transformed for parametric analyses.
Serum Phosphorus, Dietary Phosphorus Density and
Albuminuria
We first examined whether we could detect a relationship
between serum phosphorus or dietary phosphorus intake and
albuminuria in this large normal population. We found no
increase in log-transformed ACR or FEalb with increasing quintile
of serum phosphorus concentration (Table 2). In fact, following
adjustment for metabolic syndrome components (models 2/3),
quintiles 2–5 were associated with a statistically significantly lower
FEalb than quintile 1. Spot urine concentrations of both albumin
and creatinine were significantly lower with increasing phosphorus
quintile, although differences were somewhat attenuated by full
covariate adjustment. Elevations of serum phosphorus within the
normal range therefore are not associated with increased
albuminuria and indeed we found some evidence that the reverse
may be the case for FEalb. When these analyses were repeated in
the 8,911 participants assessed after an overnight fast, there
remained no association between higher-normal phosphorus and
albuminuria, though the associations with lower FEalb were no
longer significant (not shown).
Increasing dietary phosphorus density was also not associated
with albuminuria (Table 3). In model 1, the lowest quintile of
estimated dietary phosphorus density over the preceding 24 h
actually had a significantly greater log ACR and FEalb than
quintiles 2-5. However, full covariate adjustment (model 3)
rendered these associations nonsignificant. When dietary phos-
phorus intake was assessed indexed to weight or as absolute
unindexed intake there remained no association with greater
Table 1. Characteristics of the US population represented by
the NHANES 1999–2010, 2003–2006 and 1999–2004 cohorts.
1999–2010 2003–2006 1999–2004
N 19,383 6,005 7,384
Age, y, mean (SE) 44.8 (0.3) 45.2 (0.4) 41.4 (0.3)
Male, % (SE) 50.3 (0.3) 50.2 (0.7) 50.9 0.7)
Race, % (SE)
Nonhispanic White 76.8 (1.1) 76.4 (2.2) 77.3 (1.3)
Nonhispanic Black 9.7 (0.6) 10.4 (1.3) 9.8 (0.9)
Hispanic 8.0 (0.7 7.9 (1.1) 7.8 (1.0)
Other 4.9 (0.3) 5.0 (0.6) 4.5 (0.5)
BMI, kg/m2, mean (SE) 28.3 (0.1) 28.2 (0.2) 27.8 (0.1)
Systolic BP, mmHg, mean (SE) 121.4 (0.2) 122.3 (0.4) 120.8 (0.4)
Diastolic BP, mmHg, mean (SE) 71.6 (0.2) 71.3 (0.3) 72.7 (0.2)
Diabetes, % (SE) 6.2 (0.2) 6.0 (0.4) 4.3 (0.3)
Cardiovascular disease, % (SE) 4.5 (0.2) 4.9 (0.4) 3.9 (0.3)
Smoking, % (SE) 29.8 (0.6) 31.4 (1.1) 32.6 (1.1)
eGFR, ml/min/1.73 m2, mean (SE) 96.8 (0.3) 96.1 (0.6) 98.4 (0.5)
Serum phosphorus, mg/dL,
mean (SE)
3.71 (0.01) 3.83 (0.01) 3.65 (0.01)
24 h phosphorus intake, mg,
mean (SE)
1393 (7) 1383 (16) 1387 (13)
Serum calcium, mg/dL, mean (SE) 9.47 (0.01) 9.54 (0.01) 9.48 (0.02)
PTH, pg/mL, median (IQR) NA 38 (21) NA
Total ALP, U/L, median (IQR) 66 (26) 64 (24) 67 (27)
25(OH) vitamin D, ng/mL, mean (SE) NA 24.0 (0.4) NA
BAP, ug/L, median (IQR) NA NA 13.8 (6.8)
ACR, mg/g, median (IQR) 5.8 (6.2) 5.9 (6.2) 5.6 (5.9)
Urine albumin, mg/L, median (IQR) 6.8 (9.1) 6.9 (9.3) 6.9 (9.5)
Moderate albuminuria, % (SE) 10.2 (0.3) 10.1 (0.4) 9.4 (0.5)
Data are given as mean (standard deviation) or median (interquartile range) for
parametric and non-parametrically distributed variables respectively. N/A, not
available.
SE, standard error; IQR, interquartile range.
doi:10.1371/journal.pone.0088388.t001
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Table 2. Measures of albuminuria according to quintile of serum phosphorus.
Serum phosphorus quintile (mg/dl)
,3.3 3.3-,3.6 3.6-,3.9 3.9-,4.2 $4.2
Model 1
uAlb 1 0.96 (0.89, 1.02) p = 0.20 0.90 (0.84, 0.96) p = 0.003 0.84 (0.78, 0.90) p,0.001 0.86 (0.80, 0.92) p,0.001
uCr 1 0.96 (0.92, 1.00) p = 0.056 0.94 (0.90, 0.98) p = 0.004 0.88 (0.84, 0.82) p,0.001 0.89 (0.86, 0.94) p,0.001
ACR 1 1.00 (0.95, 1.05) p = 0.94 0.96 (0.91, 1.01) p = 0.11 0.96 (0.91, 1.01) p = 0.089 0.96 (0.92, 1.01) p = 0.15
FEalb 1 0.99 (0.94, 1.04) p = 0.74 0.95 (0.91, 1.00) p = 0.071 0.94 (0.90, 0.99) p = 0.03 0.96 (0.91, 1.01) p = 0.10
Model 2
uAlb 1 0.97 (0.90, 1.03) p = 0.29 0.92 (0.86, 0.99) p = 0.018 0.85 (0.79, 0.91) p,0.001 0.87 (0.81, 0.93) p,0.001
uCr 1 0.97 (0.93, 1.01) p = 0.12 0.95 (0.91, 0.99) p = 0.022 0.90 (0.86, 0.94) p,0.001 0.91 (0.87, 0.95) p,0.001
ACR 1 1.00 (0.95, 1.05) p = 0.94 0.97 (0.92, 1.02) p = 0.22 0.95 (0.90, 1.00) p = 0.033 0.96 (0.91, 1.01) p = 0.095
FEalb 1 0.99 (0.94, 1.04) p = 0.75 0.97 (0.92, 1.01) p = 0.16 0.94 (0.89, 0.99) p = 0.016 0.95 (0.90, 1.00) p = 0.032
Model 3
uAlb 1 0.97 (0.92, 1.03) p = 0.36 0.94 (0.89, 1.00) p = 0.051 0.93 (0.87, 0.99) p = 0.016 0.92 (0.87, 0.98) p = 0.010
uCr 1 0.97 (0.94, 1.01) p = 0.12 0.97 (0.93, 1.01) p = 0.10 0.95 (0.92, 0.99) p = 0.017 0.96 (0.93, 1.00) p = 0.066
ACR 1 1.00 (0.96, 1.05) p = 0.49 0.97 (0.93, 1.02) p = 0.72 0.97 (0.93, 1.02) p = 0.58 0.96 (0.91, 1.00) p = 0.62
FEalb 1 0.93 (0.89, 0.98) p = 0.008 0.94 (0.89, 0.98) p = 0.006 0.93 (0.89, 0.98) p = 0.004 0.93 (0.88, 0.98) p = 0.006
model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes
status, HbA1C.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, hemoglobin, calcium, time of day of
venepuncture.
uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FEalb, fractional excretion of albumin relative to creatinine.
doi:10.1371/journal.pone.0088388.t002
Table 3. Measures of albuminuria according to quintile of estimated dietary phosphorus density.
Dietary phosphorus density (mg/kcal)
,0.49 0.49-,0.57 0.57-,0.66 0.66-,0.77 $0.77
Model 1
uAlb 1 0.88 (0.82, 0.94) p,0.001 0.86 (0.80, 0.92) p,0.001 0.81 (0.75, 0.86) p,0.001 0.77 (0.71, 0.82) p,0.001
uCr 1 0.94 (0.90, 0.98) p = 0.005 0.92 (0.88, 0.96) p,0.001 0.87 (0.83, 0.91) p,0.001 0.83 (0.79, 0.87) p,0.001
ACR 1 0.93 (0.89, 0.98) p = 0.008 0.94 (0.89, 0.98) p = 0.006 0.93 (0.89, 0.98) p = 0.004 0.93 (0.88, 0.98) p = 0.006
FEalb 1 0.93 (0.88, 0.98) p = 0.004 0.93 (0.89, 0.98) p = 0.004 0.93 (0.88, 0.97) p = 0.003 0.92 (0.87, 0.97) p = 0.002
Model 2
uAlb 1 0.90 (0.84, 0.96) p = 0.002 0.88 (0.82, 0.95) p = 0.001 0.84 (0.78, 0.90) p,0.001 0.81 (0.74, 0.88) p,0.001
uCr 1 0.94 (0.90, 0.99) p = 0.01 0.92 (0.88, 0.96) p = 0.001 0.86 (0.82, 0.91) p,0.001 0.82 (0.78, 0.87) p,0.001
ACR 1 0.95 (0.90, 1.00) p = 0.04 0.96 (0.92, 1.01) p = 0.14 0.97 (0.92, 1.02) p = 0.26 0.98 (0.92, 1.04) p = 0.50
FEalb 1 0.95 (0.90, 0.99) p = 0.03 0.96 (0.91, 1.01) p = 0.11 0.96 (0.91, 1.02) p = 0.19 0.97 (0.91, 1.03) p = 0.39
Model 3
uAlb 1 0.91 (0.85, 0.97) p = 0.007 0.90 (0.84, 0.97) p = 0.005 0.86 (0.80, 0.92) p,0.001 0.83 (0.76, 0.90) p,0.001
uCr 1 0.95 (0.91, 0.99) p = 0.02 0.93 (0.89, 0.97) p = 0.001 0.87 (0.83, 0.92) p,0.001 0.84 (0.79, 0.89) p,0.001
ACR 1 0.96(0.91, 1.01) p = 0.09 0.98 (0.93, 1.04) p = 0.34 0.98 (0.93, 1.04) p = 0.55 0.99 (0.93, 1.05) p = 0.73
FEalb 1 0.96 (0.91, 1.01) p = 0.08 0.98 (0.93, 1.03) p = 0.32 0.98 (0.93, 1.04) p = 0.52 0.99 (0.93, 1.05) p = 0.72
model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes
status, HbA1c and estimated 24 h calorie-indexed dietary intakes of sodium, protein and saturated fat.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, hemoglobin, calcium.
uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FEalb, fractional excretion of albumin relative to creatinine.
doi:10.1371/journal.pone.0088388.t003
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albuminuria (not shown). Thus we found no evidence that a
greater dietary phosphorus exposure over the preceding 24 h
increased albuminuria.
Parathyroid Hormone and Albuminuria
We next examined the relationship between PTH levels and
albuminuria. NHANES participants in the top quintile of serum
PTH ($54 pg/ml) had significantly greater log ACR and FEalb
compared to quintile 1 (,27 pg/ml) in model 1 (Table 4).
Adjusting for covariates including metabolic syndrome compo-
nents, cardiovascular risk factors, eGFR, poverty:income ratio,
smoking status, CRP, hemoglobin, calcium, time of day of
venepuncture, diabetes, diuretic use, season of measurement,
and 25(OH)D (model 4) strengthened these associations, with
statistically significant increases in ACR in the highest three
quintiles of serum PTH (1.11, 1.11 and 1.19 fold respectively).
In case the excess of albuminuria in the highest quintile was
influenced by primary hyperparathyroidism, we excluded subjects
with PTH levels outside the reference range (i.e. above the 95th
centile of PTH, 75 pg/ml). This did not materially alter the
findings; the fold-change in geometric mean ACR adjusted for all
other covariates was only slightly reduced to 1.16 (1.05–1.28,
p = 0.003) for the 5th versus 1st PTH quintile.
Serum 25(OH) Vitamin D and Albuminuria
When we examined the relationship between serum vitamin D
and albuminuria we found that the lowest quintile of serum
25(OH)D (,16 ng/ml) compared with the highest quintile
($31 ng/ml) was associated with increased log-transformed
ACR and FEalb in model 1 (Table 5). However, following
adjustment for additional covariates (models 2–4) these associa-
tions were no longer significant.
Alkaline Phosphatase and Albuminuria
The top quintile of total serum ALP ($83 U/L) was associated
with significantly greater log-transformed ACR and FEalb
(Table 6). This association was attenuated when adjusted for
diabetes status, BMI, lipids, blood pressure and eGFR (model 2),
and was abolished with adjustment for further covariates including
CRP (model 3).
An association between quintile 5 versus quintile 1 of bone-
specific ALP and log-transformed ACR was attenuated by full
covariate adjustment (model 3) but still significant (Table 7).
However, the accompanying association with FEalb did not persist.
Odds Ratios of Microalbuminuria
In binary logistic regression analyses, the odds ratios of
moderately increased albuminuria (ACR.30 mg/g) were not
Table 4. Measures of albuminuria according to quintile of serum parathyroid hormone.
Parathyroid Hormone Quintile (pg/ml)
,27 27-,34 34-,42 42-,54 $54
Model 1
uAlb 1 1.09 (0.97, 1.24) p = 0.15 1.16 (1.03, 1.31) p = 0.018 1.28 (1.12, 1.45) p,0.001 1.34 (1.18, 1.52) p,0.001
uCr 1 1.08 (0.99, 1.18) p = 0.07 1.13 (1.04, 1.23) p = 0.005 1.22 (1.12, 1.33) p,0.001 1.19 (1.10, 1.30) p,0.001
ACR 1 1.01 (0.93, 1.10) p = 0.80 1.03 (0.94, 1.12) p = 0.55 1.05 (0.95, 1.15) p = 0.33 1.12 (1.02, 1.23) p = 0.015
FEalb 1 1.02 (0.93, 1.11) p = 0.71 1.03 (0.94, 1.12) p = 0.58 1.05 (0.96, 1.15) p = 0.33 1.14 (1.04, 1.25) p = 0.005
Model 2
uAlb 1 1.10 (0.97, 1.24) p = 0.13 1.16 (1.02, 1.31) p = 0.019 1.26 (1.11, 1.42) p,0.001 1.30 (1.15, 1.47) p,0.001
uCr 1 1.07 (0.99, 1.17) p = 0.091 1.10 (1.01, 1.20) p = 0.022 1.20 (1.10, 1.30) p,0.001 1.16 (1.06, 1.26) p,0.001
ACR 1 1.02 (0.94, 1.11) p = 0.63 1.05 (0.96, 1.14) p = 0.32 1.05 (0.96, 1.15) p = 0.31 1.12 (1.02, 1.23) p = 0.009
FEalb 1 1.02 (0.94, 1.12) p = 0.60 1.04 (0.95, 1.13) p = 0.40 1.04 (0.95, 1.14) p = 0.36 1.13 (1.03, 1.23) p = 0.009
Model 3
uAlb 1 1.14 (1.02, 1.29) p = 0.027 1.24 (1.10, 1.40) p,0.001 1.34 (1.18, 1.52) p,0.001 1.39 (1.22, 1.57) p,0.001
uCr 1 1.08 (0.99, 1.17) p = 0.076 1.12 (1.03, 1.22) p = 0.006 1.21 (1.11, 1.31) p,0.001 1.17 (1.07, 1.27) p,0.001
ACR 1 1.06 (0.97,1.16) p = 0.18 1.10 (1.01, 1.20) p = 0.032 1.11 (1.01, 1.21) p = 0.031 1.19 (1.09, 1.30) p,0.001
FEalb 1 1.05 (0.97, 1.15) p = 0.24 1.09 (1.00, 1.18) p = 0.062 1.09 (0.99, 1.19) p = 0.069 1.17 (1.06, 1.28) p,0.001
Model 4
uAlb 1 1.14 (1.01, 1.28) p = 0.029 1.23 (1.09, 1.40) p,0.001 1.33 (1.17, 1.51) p,0.001 1.37 (1.20, 1.55) p,0.001
uCr 1 1.07 (0.99, 1.16) p = 0.10 1.11 (1.02, 1.21) p = 0.011 1.19 (1.10, 1.30) p,0.001 1.15 (1.05, 1.25) p = 0.002
ACR 1 1.07 (0.98, 1.16) p = 0.14 1.11 (1.02, 1.21) p = 0.020 1.11 (1.01, 1.22) p = 0.029 1.19 (1.08, 1.31) p,0.001
FEalb 1 1.06 (0.97, 1.15) p = 0.20 1.09 (1.00, 1.19) p = 0.043 1.09 (1.00, 1.20) p = 0.068 1.17 (1.07, 1.28) p = 0.001
model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes
status, HbA1c.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking status, CRP, hemoglobin, calcium, time of day of
venepuncture,
model 4: as model 3 but additionally adjusted for 25(OH)D quintile, season of measurement, loop diuretic and thiazide diuretic.
uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FEalb, fractional excretion of albumin relative to creatinine.
doi:10.1371/journal.pone.0088388.t004
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significantly different by quintile of any bone mineral metabolic
parameter following covariate adjustment (not shown).
Discussion
Targeting the bone mineral metabolic axis for cardiovascular
risk prevention is an attractive but unproven strategy. We report
an independent association between higher ‘normal’ PTH and
increasing low grade albuminuria, suggesting that the higher-
normal range of PTH observed in the non-institutionalized US
population may be associated with poorer vascular health. The
magnitude of the albuminuria increase associated with PTH is
modest, but an independent linear relationship between log ACR
and cardiovascular mortality exists even at the lowest levels of
ACR[19]. Although this observational analysis does not demon-
strate a causative relationship, our finding is consistent with
evidence linking increased PTH to endothelial/microvascular
dysfunction. Such evidence comes mainly from the context of
surgical correction of primary hyperparathyroidism[43–45], a
state well known to be associated with increased cardiovascular
mortality[46]. However, even across the normal range, higher
PTH is accompanied by a substantially increased risk of
cardiovascular events and mortality[5–7]. Some studies have
reported associations between PTH and metabolic syndrome
components[47], but in the NHANES 2001–2006 cohort, diastolic
blood pressure is the only cardiovascular risk factor independently
associated with greater PTH[48]. As with the reported association
between PTH and cardiovascular mortality, we find that higher-
normal PTH is associated with greater albuminuria independently
of all traditional risk factors and previous history of cardiovascular
disease.
Possible pathways to microvascular toxicity through which PTH
could increase urinary albumin leak include oxidative stress
induced by intracellular calcium accumulation[43], induction of a
pro-inflammatory endothelial phenotype[15], or secondary eleva-
tions in aldosterone[49]. Alternatively, PTH may itself be acting as
an oxidative stress marker, since oxidized PTH is inactive but not
distinguished by standard PTH assays[50]. Although we excluded
subjects with excretory renal impairment and adjusted for eGFR,
proximal tubular dysfunction is a potential confounder that could
result in both reduced albumin reabsorption and less production of
PTH-suppressing calcitriol.
Targeted lowering of higher-normal PTH using calcitriol or the
calcimimetic agent cinacalcet might help determine whether a
higher-normal PTH plays a causal role in vascular dysfunction
and low grade albuminuria. However, both of these interventions
may have PTH-independent effects on the vasculature[51,52].
Although a number of factors are associated with a higher-normal
PTH[53], what causes a healthy individual to have a PTH in the
top quintile (thus what might best be targeted to lower PTH) is
unclear. Investigating causal relationships between metabolic bone
parameters and vascular disease is further complicated by the fact
that manipulating one parameter commonly has secondary effects
on the others[3].
Table 5. Measures of albuminuria according to quintile of serum 25(OH) vitamin D.
25(OH) vitamin D quintile (ng/ml)
Model 1 ,16 16-,22 22-,26 26-,31 $31
uAlb 1.37 (1.19, 1.57) p,0.001 1.15 (1.02, 1.29) p = 0.021 1.20 (1.06, 1.36) p = 0.0039 1.08 (0.95, 1.23) p = 0.22 1
uCr 1.18 (1.08, 1.29) p,0.001 1.13 (1.04, 1.22) p = 0.0037 1.10 (1.01, 1.19) p = 0.029 1.09 (1.00, 1.19) p = 0.041 1
ACR 1.16 (1.05, 1.28) p = 0.003 1.03 (0.94, 1.11) p = 0.63 1.09 (1.00, 1.20) p = 0.049 0.99 (0.91, 1.09) p = 0.86 1
FEalb 1.12 (1.01, 1.23) p = 0.028 1.00 (0.92, 1.09) p = 0.94 1.07 (0.98, 1.17) p = 0.12 0.98 (0.90, 1.08) p = 0.69 1
Model 2
uAlb 1.20 (1.04, 1.39) p = 0.011 1.07 (0.95, 1.20) p = 0.26 1.14 (1.01, 1.29) p = 0.038 1.06 (0.93, 1.20) p = 0.38 1
uCr 1.11 (1.01, 1.21) p = 0.026 1.08 (0.99, 1.17) p = 0.072 1.05 (0.97, 1.15) p = 0.20 1.06 (0.98, 1.16) p = 0.14 1
ACR 1.08 (0.98, 1.20) p = 0.11 0.99 (0.92, 1.08) p = 0.88 1.08 (0.99, 1.18) p = 0.085 0.99 (0.91, 1.08) p = 0.87 1
FEalb 1.03 (0.93, 1.14) p = 0.57 0.97 (0.89, 1.05) p = 0.42 1.05 (0.96, 1.14) p = 0.28 0.98 (0.89, 1.07 p = 0.59 1
Model 3
uAlb 1.21 (1.05, 1.39) p = 0.010 1.08 (0.96, 1.22) p = 0.19 1.15 (1.02, 1.30) p = 0.025 1.07 (0.94, 1.21) p = 0.31 1
uCr 1.15 (1.05, 1.25) p = 0.032 1.10 (1.02, 1.19) p = 0.019 1.07 (0.99, 1.16) p = 0.085 1.08 (0.99, 1.17) p = 0.079 1
ACR 1.05 (0.95, 1.16) p = 0.31 0.98 (0.91 1.07) p = 0.71 1.07 (0.98, 1.17) p = 0.11 0.99 (0.91, 1.08) p = 0.84 1
FEalb 1.05 (0.95, 1.16) p = 0.30 0.99 (0.91, 1.07) p = 0.76 1.07 (0.98, 1.16) p = 0.13 0.99 (0.91, 1.08) p = 0.084 1
Model 4
uAlb 1.15 (0.99, 1.33) p = 0.067 1.04 (0.93, 1.17) p = 0.50 1.14 (1.00, 1.29) p = 0.042 1.05 (0.93, 1.19) p = 0.40 1
uCr 1.13 (1.03, 1.23) p = 0.010 1.08 (1.00, 1.17) p = 0.053 1.07 (0.99, 1.16) p = 0.088 1.07 (0.99, 1.16) p = 0.080 1
ACR 1.02 (0.92, 1.13) p = 0.72 0.96 (0.89, 1.05) p = 0.38 1.06 (0.97, 1.16) p = 0.19 0.98 (0.90, 1.07) p = 0.67 1
FEalb 1.03 (0.93, 1.14) p = 0.61 0.97 (0.89, 1.05) p = 0.47 1.06 (0.97, 1.16) p = 0.18 0.98 (0.90, 1.07) p = 0.72 1
model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes
status, HbA1c.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking status, 25(OH)vitamin D, CRP, hemoglobin, calcium
and season of measurement.
model 4: as model 3 but additionally adjusted for PTH quintile and time of day of venepuncture.
uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FEalb, fractional excretion of albumin relative to creatinine.
doi:10.1371/journal.pone.0088388.t005
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Notably, our findings linking PTH to albuminuria were
independent of 25(OH)D, which was not itself associated with
urinary albumin leak. This is consistent with the results of a recent
study from the Korean National Health and Nutrition Examina-
tion Survey, where ascending quartile of PTH in participants
.50 y was associated with increased odds of ACR.10 mg/g, but
lower 25(OH)D quartile did not associate with albuminuria[54].
In contrast, a previous report from the third US NHANES cohort
showed an association between lower 25(OH)D and the preva-
lence of moderately increased albuminuria[55]. However, that
Table 6. Measures of albuminuria according to quintile of total alkaline phosphatase.
Total ALP quintile (U/L)
Model 1 ,51 51-,61 61-,71 71-,83 $83
uAlb 1 1.01 (0.95, 1.08) p = 0.63 1.12 (1.06, 1.19) p,0.001 1.13 (1.06, 1.21) p,0.001 1.31 (1.23, 1.39) p,0.001
uCr 1 1.02 (0.98, 1.06) p = 0.45 1.08 (1.03, 1.12) p,0.001 1.10 (1.05, 1.14) p,0.001 1.10 (1.05, 1.14) p,0.001
ACR 1 1.00 (0.96, 1.04) p = 0.97 1.05 (1.00, 1.09) p = 0.046 1.03 (0.99, 1.08) p = 0.16 1.19 (1.14, 1.25) p,0.001
FEalb 1 0.99 (0.95, 1.04) p = 0.72 1.04 (1.00, 1.09) p = 0.068 1.02 (0.98, 1.07) p = 0.32 1.18 (1.13, 1.24) p,0.001
Model 2
uAlb 1 0.98 (0.91, 1.05) p = 0.53 1.05 (0.98, 1.12) p = 0.18 1.05 (0.98, 1.13) p = 0.14 1.12 (1.05, 1.20) p = 0.001
uCr 1 1.00 (0.96, 1.05) p = 0.88 1.05 (1.00, 1.10) p = 0.064 1.07 (1.02, 1.12) p = 0.007 1.06 (1.01, 1.11) p = 0.015
ACR 1 0.97 (0.93, 1.02) p = 0.30 1.00 (0.95, 1.05) p = 0.92 0.99 (0.94, 1.04) p = 0.63 1.06 (1.01, 1.11) p = 0.024
FEalb 1 0.97 (0.93, 1.02) p = 0.27 1.00 (0.95, 1.05) p = 0.97 0.98 (0.93, 1.03) p = 0.45 1.06 (1.00, 1.11) p = 0.032
Model 3
uAlb 1 0.97 (0.91, 1.03) p = 0.29 1.03 (0.97, 1.10) p = 0.29 1.01 (0.95, 1.07) p = 0.74 1.08 (1.01, 1.15) p = 0.018
uCr 1 1.00 (0.96, 1.04) p = 0.94 1.04 (1.00, 1.09) p = 0.039 1.06 (1.02, 1.10) p = 0.007 1.04 (1.00, 1.09) p = 0.037
ACR 1 0.97 (0.93, 1.01) p = 0.17 0.99 (0.95, 1.03) p = 0.67 0.96 (0.91, 1.00) p = 0.046 1.03 (0.99, 1.09) p = 0.18
FEalb 1 0.97 (0.93, 1.01) p = 0.16 0.99 (0.95, 1.03) p = 0.66 0.96 (0.91, 1.00) p = 0.030 1.03 (0.98, 1.08) p = 0.19
model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes
status, HbA1c.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, alanine transaminase, aspartate transaminase,
hemoglobin, calcium, phosphorus.
uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FEalb, fractional excretion of albumin relative to creatinine.
doi:10.1371/journal.pone.0088388.t006
Table 7. Measures of albuminuria according to quintile of bone-specific alkaline phosphatase.
Bone-specific ALP quintile (ug/L)
Model 1 ,3.3 3.3-,3.6 3.6-,3.9 3.9-,4.2 $4.2
uAlb 1 1.18 (1.05, 1.32) p = 0.004 1.15 (1.04, 1.29) p = 0.013 1.22 (1.09, 1.36) p,0.001 1.46 (1.30, 1.64) p,0.001
uCr 1 1.11 (1.02, 1.19) p = 0.014 1.11 (1.03, 1.21) p = 0.007 1.14 (1.05, 1.24) p = 0.001 1.14 (1.05, 1.23) p = 0.001
ACR 1 1.07 (0.99, 1.16) p = 0.086 1.03 (0.96, 1.12) p = 0.40 1.07 (0.98, 1.16) p = 0.13 1.29 (1.18, 1.40) p,0.001
FEalb 1 1.06 (0.98, 1.14) p = 0.15 1.01 (0.93, 1.09) p = 0.82 1.04 (0.96, 1.13) p = 0.29 1.24 (1.14, 1.35) p,0.001
Model 2
uAlb 1 1.14 (1.01, 1.27) p = 0.025 1.08 (0.97, 1.21) p = 0.17 1.12 (1.00, 1.26) p = 0.050 1.28 (1.14, 1.44) p,0.001
uCr 1 1.09 (1.01, 1.18) p = 0.024 1.09 (1.01, 1.18) p = 0.034 1.13 (1.04, 1.22) p = 0.002 1.14 (1.05, 1.23) p = 0.002
ACR 1 1.04 (0.96, 1.12) p = 0.84 0.99 (0.92, 1.08) p = 0.86 0.99 (0.92, 1.08) p = 0.84 1.13 (1.04, 1.23) p = 0.004
FEalb 1 1.03 (0.95, 1.11) p = 0.49 0.97 (0.89, 1.05) p = 0.39 0.97 (0.90, 1.06) p = 0.53 1.09 1.01, 1.19) p = 0.037
Model 3
uAlb 1 1.12 (1.01, 1.26) p = 0.038 1.07 (1.05, 1.19) p = 0.26 1.09 (1.02, 1.23) p = 0.12 1.24 (1.11, 1.40) p,0.001
uCr 1 1.09 (1.01, 1.18) p = 0.024 1.09 1.01, 1.18) 0.024 1.12 (1.04, 1.21) p = 0.004 1.14 (1.05, 1.23) p = 0.002
ACR 1 1.03 (0.95, 1.11) p = 0.45 0.97 0.90, 1.05) p = 0.50 0.98 (0.90, 1.06) p = 0.57 1.10 (1.01, 1.19) p = 0.035
FEalb 1 1.02 (0.95, 1.10) p = 0.55 0.96 (0.89, 1.04) p = 0.33 0.96 (0.88, 1.04) p = 0.30 1.07 (0.99, 1.17) p = 0.11
model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes
status, HbA1c.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking status, CRP, hemoglobin, calcium.
doi:10.1371/journal.pone.0088388.t007
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analysis was not confined to participants with preserved excretory
renal function and did not adjust for pre-existing cardiovascular
disease or inflammatory markers. Consequently, the reported
association may at least partly reflect residual confounding by
lifestyle or creatininuria; subjects with cardiovascular or other
comorbidity are less physically active and so have less muscle mass
(thus increasing ACR independently of albumin excretion) and less
sun exposure (thus lower 25(OH)D).
In contrast to a previous report from the Korean NHANES
cohort[56], our study did not find any association between
increasing serum phosphorus and greater albuminuria. If
anything, the reverse was observed. Other than the different
populations studied, the reasons for this discrepancy are not clear.
Toxic effects of increasing phosphate concentrations on endothe-
lial cells in vitro have been reported, but only at levels well above
the normal range[3,14,57]. Whether endothelial dysfunction plays
any role in the observed association between higher-normal serum
phosphorus and cardiovascular events or kidney disease is
unknown. Our findings do not provide any evidence to support
a toxic vascular effect of increasing serum phosphorus across the
normal range.
Shuto et al. reported an acute decline in endothelial-dependent
brachial artery flow-mediated dilation following dietary phospho-
rus ingestion[14], raising concerns that excessive bioavailable
phosphorus in Western diets contributes to the accrual of vascular
damage[3,4,58]. Dietary phosphorus intake might exert adverse
vascular effects through post-prandial serum phosphorus peaks or
through secondary changes in regulatory hormones such as
parathyroid hormone, fibroblast growth factor-23[59] and calci-
triol. A reduction in 24 h urine phosphorus, taken as a reflection of
lower dietary phosphorus intake, was an independent predictor of
albuminuria reduction in the PREMIER study of lifestyle
interventions in obese subjects with preserved kidney function[60].
However, we did not find any association between greater
estimated dietary phosphorus intake and increasing low-grade
albuminuria. Dietary intake estimates were based on a single 24 h
record; although a more prolonged assessment period might reveal
an association between dietary phosphorus exposure and albu-
minuria, this time period was reported sufficient to detect an
association with cardiovascular mortality[4].
Alkaline phosphatase is expressed in liver, kidneys, intestine and
leukocytes as well as bone. In the NHANES 1999–2004 cohort the
non-bone fraction of ALP, but not bone-specific ALP, was shown
to be a mortality predictor[61], perhaps acting as a marker of
inflammation and neutrophil activation. Conversely, in dialysis
patients bone-specific ALP is a stronger predictor of cardiovascular
mortality than total ALP, which may reflect an important link
between bone-type ALP and arterial calcification[62]. We find
that adjustment for covariates including CRP, metabolic syn-
drome factors and history of cardiovascular disease renders an
association between total ALP and greater low grade albuminuria
nonsignificant. Surprisingly, an association between bone-specific
ALP and greater albuminuria remained significant despite full
covariate adjustment. However, quantifying renal albumin
permeability as FEalb did not confirm this finding, which was
thus less robust than the association between albuminuria and
higher-normal PTH.
Although PTH was the only metabolic bone parameter that
demonstrated a robust association with increasing low grade
albuminuria, this does not mean that the ‘normal’ ranges of the
other parameters are optimal for vascular health. There may be
important adverse effects of subtle bone metabolic disturbances on
endothelium or other vascular tissues that do not lead to increased
albumin leak. Cardiovascular risk might also be mediated through
other factors for which we adjusted, for example hypertension,
insulin resistance and systemic inflammation[47,48,61]_EN-
REF_57.
Limitations
Our study has some limitations. Firstly, albuminuria assessments
were performed on only a single urine sample from each
participant. Since there is known to be intra-individual variation
on repeat testing[63] this may have limited our ability to detect
associations of modest magnitude. Similarly, dietary phosphorus
intake and serum phosphorus concentration vary over time within
individuals[35] so single measurements of these parameters may
also limit the capture of associations. Dietary phosphorus intake
estimates did not distinguish inorganic phosphates from organic
phosphates, though the greater bioavailability of the former could
have physiological consequences[64]. Another limitation is the
lack of fibroblast growth factor-23 and calcitriol measurements;
compensatory changes in these hormones occur in response to
increased dietary phosphorus intake and might be important
mediators of vascular dysfunction[3]. Finally, although our
analyses adjusted for traditional vascular risk factors and C-
reactive protein, other predictors of albuminuria have been
identified for which we did not have measurement data. For
example, a number of alternative inflammatory markers associate
with higher urine albumin excretion independently of vascular risk
factors in community populations[65].
Conclusion
Of the various metabolic bone parameters associated with
cardiovascular mortality across their normal ranges, only PTH is
independently and robustly associated with increasing low grade
albuminuria in a representative healthy population sample.
Whether interventions to re-set the metabolic bone axis improve
cardiovascular outcomes remains to be determined. However, the
two principle suspects for prevalent disturbance of the axis,
excessive dietary phosphorus exposure and inadequate vitamin D
synthesis, were not themselves associated with higher albuminuria.
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